Clinical trials
Gallbladder Neoplasms trials in South Korea
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 9 |
| Recruiting | 6 |
| Unknown status | 5 |
| Active, not recruiting | 2 |
| Terminated | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Yonsei University | 4 |
| Asan Medical Center | 2 |
| AstraZeneca | 2 |
| EMD Serono Research & Development Institute, Inc. | 2 |
| Jazz Pharmaceuticals | 2 |
| Merck Sharp & Dohme LLC | 2 |
| Samsung Medical Center | 2 |
| ASLAN Pharmaceuticals | 1 |
| Ajou University School of Medicine | 1 |
| Bayer | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Gallbladder Neoplasms | 25 |
| Cholangiocarcinoma | 15 |
| Biliary Tract Neoplasms | 12 |
| Pancreatic Neoplasms | 8 |
| Bile Duct Neoplasms | 5 |
| Esophageal Neoplasms | 4 |
| Ovarian Neoplasms | 4 |
| Breast Neoplasms | 3 |
| Colorectal Neoplasms | 3 |
| Endometrial Neoplasms | 3 |
Trials
Showing 51 to 25 of 25. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.